NCT02099539 - QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 6, 2014

Primary Completion Date

June 19, 2018

Study Completion Date

June 19, 2018

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL

N-803

Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles

Trial Locations (4)

14263

Roswell Park Cancer Institute, Buffalo

19107

Thomas Jefferson University, Philadelphia

55455

University of Minnesota Masonic Cancer Center, Minneapolis

63110

Washington University School of Medicine, St Louis